Q1 2026 Ionis Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Ionis Pharmaceuticals Inc (IONS) reported a significant increase in first-quarter revenue, up 87% compared to the same period in 2025, driven by strong commercial performance and milestone payments.
- The company successfully launched Tryngolza and DAWNZERA, with Tryngolza showing strong demand and DAWNZERA contributing significantly to commercial revenue.
- Ionis Pharmaceuticals Inc (IONS) received FDA priority review for olozorsen, with a PDUFA date set for June 30, and increased its peak sales estimate for the drug to over $3 billion.
- The company is on track for multiple independent launches in 2026, including Zilganersen for Alexander's disease, which has also received FDA priority review.
- Ionis Pharmaceuticals Inc (IONS) maintains a strong financial position with approximately $1.9 billion in cash, supporting ongoing strategic investments and future growth.
- Despite strong demand, Tryngolza's revenue was impacted by an anticipated decline in net price, which may affect short-term financial performance.
- The company faces challenges in payer access for olozorsen, as some payers may wait for the final label before making coverage decisions, potentially delaying market penetration.
- Ionis Pharmaceuticals Inc (IONS) anticipates a significant decline in second-quarter Tryngolza revenue due to a price reset, which could impact overall revenue growth.
- The launch of DAWNZERA is in a competitive market, and while initial metrics are positive, it will take time to transition patients from existing therapies.
- Operating expenses increased by 29% year-over-year, driven by commercial investments, which could pressure profitability if revenue growth does not meet expectations.
Good day, and welcome to Ionis' first quarter 2020 financial results conference call. As a reminder, this call is being recorded. At this time, I would like to turn the over to Wade Walke, Senior Vice President of Investor Relations, to lead off the call. Please begin.
Thank you, Sabrina. Before we begin, I encourage everyone to go to the Investors section of the Ionis website to view the press release and related financial tables we will be discussing today, including a reconciliation of GAAP to non-GAAP financials. We believe non-GAAP financial results better represent the economics of our business and how we manage our business.
We have also posted slides on our website that accompany today's call. With me this morning are Brett Monia, Chief Executive Officer; Kyle Jenne, Chief Global Product Strategy Officer; and Beth Hougen, Chief Financial Officer. Holly Kordasiewicz, Chief Development Officer; Eugene Schneider, Chief Clinical Development Officer; and Eric Swayze,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
